Reviva Pharmaceuticals Holdings logo

Reviva Pharmaceuticals HoldingsNASDAQ: RVPH

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

18 October 2018

Next earnings report:

14 November 2024

Last dividends:

N/A

Next dividends:

N/A
$34.42 M
-80%vs. 3y high
31%vs. sector
-vs. 3y high
-vs. sector
-106%vs. 3y high
5%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 01 Nov 2024 21:31:24 GMT
$1.04-$0.06(-5.45%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

RVPH Latest News

Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit
globenewswire.com08 October 2024 Sentiment: POSITIVE

CUPERTINO, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit, taking place virtually October 15-17, 2024.

Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
globenewswire.com02 October 2024 Sentiment: POSITIVE

CUPERTINO, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a panel discussion at the 3rd Annual ROTH Healthcare Opportunities Conference, taking place October 9, 2024, in New York, NY.

Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension
globenewswire.com09 July 2024 Sentiment: POSITIVE

- Patent covers brilaroxazine use for treating pulmonary hypertension (PH), pulmonary arterial hypertension (PAH) in any patients including treating PH in patients with chronic obstructive pulmonary disease (COPD) or sickle cell disease (SCD)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH
prnewswire.com30 May 2024 Sentiment: NEGATIVE

NEW YORK , May 30, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Reviva Pharmaceuticals Holdings, Inc. ("Reviva" or the "Company") (NASDAQ: RVPH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference
GlobeNewsWire13 May 2024 Sentiment: POSITIVE

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva, will present new efficacy data on brilaroxazine in an animal model of idiopathic pulmonary fibrosis at the 2024 American Thoracic Society International Conference in San Diego, CA on May 17-22, 2024.

Reviva to Present at Webull LIVE! Healthcare Webinar on January 17
Accesswire10 January 2024 Sentiment: POSITIVE

CUPERTINO, CA / ACCESSWIRE / January 10, 2024 / Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva, will present at the Webull LIVE!

Reviva Pharmaceuticals: Positive Results In Phase 3 But The Stock Is Back Where It Started
Seeking Alpha02 November 2023 Sentiment: POSITIVE

Results from the phase 3 RECOVER study of Reviva Pharmaceuticals' antipsychotic brilaroxazine in schizophrenia show that the 50 mg dose beat placebo on the primary endpoint. The 15 mg dose of brilaroxazine was numerically superior to placebo on the primary endpoint, but did not reach significance. Reviva Pharmaceuticals plans to start its second phase 3 study, RECOVER-2, in Q1'24 and will need to raise additional funds to support the study.

Reviva Pharma's schizophrenia drug succeeds in late-stage study
Reuters30 October 2023 Sentiment: POSITIVE

Reviva Pharmaceuticals Holdings said on Monday its experimental drug to treat adults with schizophrenia met the main goal of a late-stage study.

Reviva Pharmaceuticals: A Binary Event Approaches With Results From RECOVER
Seeking Alpha27 September 2023 Sentiment: POSITIVE

Reviva Pharmaceuticals is running a phase 3 study of brilaroxazine in schizophrenia called RECOVER, with results expected in October 2023. A previous phase 2 study showed that brilaroxazine had significant antipsychotic activity, and a potentially differentiated side effect profile versus Abilify. RVPH had $11.2M in cash and cash equivalents at the end of Q2'23, and could fall heavily if the phase 3 study doesn't succeed.

Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in May 2023
GlobeNewsWire18 May 2023 Sentiment: NEGATIVE

CUPERTINO, Calif., May 18, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory and metabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting at two upcoming investor conferences to be held in May 2023.

What type of business is Reviva Pharmaceuticals Holdings?

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

What sector is Reviva Pharmaceuticals Holdings in?

Reviva Pharmaceuticals Holdings is in the Healthcare sector

What industry is Reviva Pharmaceuticals Holdings in?

Reviva Pharmaceuticals Holdings is in the Biotechnology industry

What country is Reviva Pharmaceuticals Holdings from?

Reviva Pharmaceuticals Holdings is headquartered in United States

When did Reviva Pharmaceuticals Holdings go public?

Reviva Pharmaceuticals Holdings initial public offering (IPO) was on 18 October 2018

What is Reviva Pharmaceuticals Holdings website?

https://www.revivapharma.com

Is Reviva Pharmaceuticals Holdings in the S&P 500?

No, Reviva Pharmaceuticals Holdings is not included in the S&P 500 index

Is Reviva Pharmaceuticals Holdings in the NASDAQ 100?

No, Reviva Pharmaceuticals Holdings is not included in the NASDAQ 100 index

Is Reviva Pharmaceuticals Holdings in the Dow Jones?

No, Reviva Pharmaceuticals Holdings is not included in the Dow Jones index

When was Reviva Pharmaceuticals Holdings the previous earnings report?

No data

When does Reviva Pharmaceuticals Holdings earnings report?

The next expected earnings date for Reviva Pharmaceuticals Holdings is 14 November 2024